B+
Bull case
25%
Probability
Target price
$2.40
+106.9% vs current
PDSB
PDS BiotechnologyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.05
-9.5% vs current
B-
Bear case
30%
Probability
Target price
$0.40
-65.5% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+51.6
Score
AI commentary
Sentiment is best framed as cautious monitoring, not a high-conviction bull case. The latest primary-source update is clinically encouraging, but the deterministic prior is neutral and the 10-K's going-concern disclosure keeps financing risk front and center. Near-term trading can react positively to the April publication, yet sustained upside likely requires either credible FDA pathway progress for VERSATILE-003 or a cleaner capital bridge.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-30catalystApril 2026 PDS01ADC Phase 2 publication could drive brief sentiment supportHigh impact
An April 15, 2026 8-K filed an Exhibit 99.1 press release highlighting published Stage 1 Phase 2 PDS01ADC data in metastatic colorectal cancer, including 77.8% ORR at six months, roughly 85% 24-month survival, and extrahepatic PFS not reached at minimum 13.1 months in a small non-randomized cohort; this can support near-term trading interest, but the dataset is early and not head-to-head [#8-K-2026-04-15].
2026-12-31eventVERSATILE-003 regulatory feedback remains the main upside inflectionHigh impact
The 2025 10-K says PDS initiated VERSATILE-003 in March 2025, amended the protocol after December 2025 FDA discussions to add progression-free survival as an interim primary endpoint, and scheduled a Type C meeting to discuss a proposed accelerated approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer; any clear FDA path or trial-progress update would matter materially [#10-K-2026-03-30].
2027-03-30catalystRunway and financing outcome will shape whether clinical optionality survivesHigh impact
The 10-K reported $26.7 million of cash at December 31, 2025, monthly debenture redemptions, a minimum cash covenant, and management's conclusion that substantial doubt exists about continuing as a going concern for at least 12 months from the filing date; that makes a financing, partnership, or other capital action a central medium-term catalyst, but also a dilution risk [#10-K-2026-03-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology